Objective To explore the value of solifenacin in managing bladder irritative symptoms after transurethral resection of bladder tumor. Methods A total of 116 patients with the diagnosis of non-muscle invasive bladder carcinoma were enrolled in the present study, and they were randomly allocated into experiment group and control group. All patients received transurethral resection of bladder cancer and immediate postoperative instillation of epirubicin. Patients in the experiment group also received solifenacin 5 mg at 6 h before surgery and once a day after surgery for 3 d, while the patients in the control group received placebo. The incidences and severity of catheter related bladder discomfort were recorded at 6, 12, 24, 48 and 72 h after surgery. Results The incidence rate of bladder irritative symptoms significantly decreased from 93.1% in the control group to 67.2% in the experiment group(P=0.001). Compared with the control group, the severity of bladder irritative symptoms in the experiment group was significantly improved at all time points (P<0.05 or P<0.01). Conclusion Solifenacin is effective for managing bladder irritative symptoms after transurethral resection of bladder tumors.